Management of metastatic castration-resistant prostate cancer: recent advances (Q38012528)

27 August 2017

title

Management of metastatic castration-resistant prostate cancer: recent advances (English)

1 reference

27 August 2017

1 reference

Deborah Mukherji

1

1 reference

27 August 2017

Andrew Eichholz

series ordinal

2

1 reference

27 August 2017

Johann S De Bono

series ordinal

3

1 reference

27 August 2017

publication date

1 May 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

1011-1028

1 reference

27 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Circulating tumor cells as biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

New Therapies for Castration-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase II study of sunitinib in men with advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

The role of Src in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Heat shock protein 90 as a drug target: some like it hot.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11633360-000000000-00000

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

21 January 2018

1 reference

12 December 2020

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

12 December 2020

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

1 reference

12 December 2020

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer

1 reference

12 December 2020

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

1 reference

12 December 2020

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo

1 reference

12 December 2020

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

1 reference

12 December 2020

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

1 reference

12 December 2020

10.2165/11633360-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1020710510

0 references

1 reference